Tag Archives | S Diarra

Assessment of DPM Medicine Regulatory System, Mali

A comprehensive assessment of DPM’s medicine regulatory system was conducted September to October 2017 by SIAPS funded by USAID. The WHO Global Benchmarking Tool was used for data collection. The scope of the assessment was focused on the five regulatory functions: national regulatory systems, medicines registration and marketing authorization (MA), pharmacovigilance (PV), market surveillance and control, and clinical trial oversight (CTO).

Read full story · Comments are closed

Guidance on Elements to Consider when Planning for the Integration of Oxytocin into the EPI Cold Chain

The purpose of this document is to provide guidance to national program managers who are considering integrating oxytocin into the EPI cold chain. It is intended for representatives from relevant offices of the Ministry of Health (MoH), such as Pharmacy, Central Medical Stores, and Maternal and Child Health, as well as other policy makers, stakeholders, and implementing partners.

This guidance document introduces the pharmaceutical management elements that must be considered to successfully integrate oxytocin into the EPI cold chain and outlines the steps that will help national program managers plan the integration processes and strategies. Integrating oxytocin into the EPI cold chain may affect several elements within the pharmaceutical management cycle, from distribution systems, inventory management, and logistics management information systems and reporting procedures to roles and responsibilities, health facility infrastructure, and monitoring and evaluation. Some elements of the pharmaceutical system are afterthoughts that are only considered when challenges arise during implementation. Taking into account all elements that will be impacted by integrating oxytocin into a supply chain will not only help identify issues but also address needed changes in standard operating procedures and at the various stages of the supply chain. It is important to consider each element and address it in the strategy and implementation plan to ensure that oxytocin integration into the EPI cold chain is successful.

Read full story · Comments are closed

Guidance for Planning the Introduction of New Reproductive, Maternal, Newborn, and Child Health Medicines and Supplies

The purpose of this document is to provide guidance to program managers in ministries of health at national and sub-national levels as well as personnel in other interested organizations on actions to take and factors to consider when expanding access to essential RMNCH commodities. While this document focuses on RMNCH medicines and supplies, it may be used as a guiding document and planning tool for other essential medicines and supplies. This guide addresses several pharmaceutical management issues (pharmaceutical policies, effective medicine management, strengthening regulatory systems, information needs, and product quality and safety practices) that are often overlooked when considering the introduction of new products. The systems strengthening approach described in this document focuses on governance, human resources, information systems, financing, and service delivery, with the provision of medical products cutting across these sub-systems. The goal of this guidance document is to assist managers to systematically plan for the successful introduction of new medicines and supplies by harmonizing and aligning efforts among all stakeholders involved in the process.

Read full story · Comments are closed

Building Systems for Access and Appropriate Use of iCCM Medicines

Briggs J, Yeager B, Diarra S. Building Systems for Access and Appropriate Use of iCCM Medicines. This seminar was presented as part of the 2016 USAID Global Health Mini-University. For more information on the Mini-University, visit www.mini-university.com.

Read full story · Comments are closed

Ensuring Access to and Appropriate Use of Medicines for iCCM: It takes a system

Briggs J, Joshi MP, Yeager B, Diarra S. Ensuring access to and appropriate use of medicines for iCCM: It takes a system. Oral presentation at the 143rd American Public Health Association (APHA) Annual Meeting and Expo, Chicago, IL, USA. November 3, 2015.

 

Read full story · Comments are closed

Étude de faisabilité de l’élargissement de l’accès aux TDR et CTA dans les pharmacies du secteur privé au Mali : Rapport de recherche

La présente étude vise à examiner la faisabilité d’une introduction des tests de diagnostic rapide (TDR) et combinaisons thérapeutiques à base d’artémisinine (CTA) subventionnés pour la prise en charge du paludisme dans les pharmacies du secteur privé au Mali, et déterminer quels éléments doivent être pris en compte afin de garantir que cette introduction s’effectue de manière réaliste, acceptable, efficace et pérenne.

Read full story · Comments are closed

Integration of Oxytocin into the Cold Chain of the Expanded Programme on Immunization: Case of Mali

Postpartum hemorrhage (PPH) still remains one of the major causes of maternal mortality, accounting for 35% of all maternal deaths. The World Health Organization (WHO) has recommended oxytocin as the most effective medicine for the prevention and treatment of PPH, particularly for facility-based births. Most countries include oxytocin on their essential medicines lists (EML) as the medicine of choice for prevention and treatment of PPH. In most countries, everal oxytocin products are registered. Despite this positive policy framework for oxytocin use, supply chain barriers that limit access to the medicine still persist in many countries. Inadequate forecasting of requirements, weak information systems, and poor distribution practices, and inability to maintain proper storage conditions—temperatures between 2 and 8 °C—throughout the supply chain are all factors contributing to this lack of availability.

In practice, in countries where the average temperature is above 30 °C and where adequate infrastructure for cold chain management is often lacking, maintaining the required storage conditions for oxytocin is a challenge. As a result, oxytocin is often provided by service delivery points outside of a temperature-controlled cold chain, compromising its effectiveness and shelf life. In most countries, EPI cold chains are highly effective in reaching even the lowest levels of the health system.  However, they are managed vertically, separately from other essential commodities. One of the barriers to integrating other products into the EPI cold chain is the perception at the country level that this is not permitted. However, some countries, such as Mali, have already attempted integration in some areas of the country and have experiences that may be useful.

The main objective of this activity was to document how oxytocin is currently distributed in Mali so that the experience may be used as a case study to inform how the integration of oxytocin into the EPI cold chain may be achieved.

 

Read full story · Comments are closed

Report on Work to Raise Awareness on the Introduction of 7.1 Percent Chlorhexidine Digluconate for Umbilical Cord Care in the Democratic Republic of the Congo

The Ministry of Health, through the Department for the Health of Families and Specific Groups (D10), organized a workshop on August 29–30, 2013, to sensitize policy makers and operational partners. This resulted in development of the outline for a strategic plan for the introduction and use of 7.1 percent CHX for umbilical cord care in the DRC. This workshop was also the first activity in the implementation of phase I of the plan to eliminate bottlenecks for the 13 life-saving medicines for women and children.

Read full story · Comments are closed